AQP4 and neuromyelitis optica: Regarding prognosis, sGFAP plays a key role in patients with AQP4-IgG NMOSD and the dynamics of this molecule has been elucidated by a prospective study conducted during the NMO-Momentum trial for inebiliziumab (126).